纳入变异底物特异性和新多态单倍型改进CYP2D6催化药物代谢预测
该转化研究分析两个大型临床队列中患者的基因型与表型,聚焦CYP2D6底物利培酮和去甲他莫昔芬的代谢,纳入新多态单倍型及CYP2D6.1、CYP2D6.2、CYP2D6.35的底物特异性差异。CYP2D6.2和CYP2D6.35在体内及体外表达模型中显示对这些底物代谢能力降低,新多态单倍型使CYP2D6活性增加30-40%,纳入预测方程后去甲他莫昔芬代谢的遗传预测R2从59%提高至71%。
要点
- CYP2D6.2和CYP2D6.35对利培酮和去甲他莫昔芬代谢能力降低。
- CYP2D6*1、*2、*35背景新单倍型使CYP2D6活性增加30-40%。
- 纳入新单倍型后去甲他莫昔芬代谢预测R2从59%升至71%。
核心结论
- 考虑药物特异性酶变异相互作用并整合不同多态单倍型可提高CYP2D6代谢的遗传预测准确性。
研究设计与样本
- 转化研究,分析两个大型临床队列患者的基因型与表型,聚焦利培酮和去甲他莫昔芬代谢。
主要发现
- CYP2D6.2和CYP2D6.35在体内及体外表达模型中对利培酮和去甲他莫昔芬代谢能力降低,表现为催化周转率(Kcat)降低、底物亲和力降低和底物对接改变。
- 在CYP2D6*1、CYP2D6*2和CYP2D6*35背景上鉴定出新多态单倍型,每种与CYP2D6活性增加30-40%相关。
- 纳入这些发现后,去甲他莫昔芬代谢的遗传预测R2从59%提高至71%。
- 利培酮(也由CYP3A4代谢)的遗传预测R2从42%提高至46%。
关键数值与推荐
- CYP2D6.2和CYP2D6.35对利培酮和去甲他莫昔芬的代谢能力降低。
- CYP2D6*1、CYP2D6*2、CYP2D6*35背景新单倍型与CYP2D6活性增加30-40%相关。
- 纳入新单倍型后去甲他莫昔芬代谢预测R2从59%提高至71%,利培酮从42%提高至46%。
临床怎么用
- 在CYP2D6药物基因组学模型和指南中应考虑药物特异性酶变异相互作用并整合不同多态单倍型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The polymorphic CYP2D6 enzyme plays a pivotal role in the metabolism of approximately 25% of clinically prescribed drugs. However, the impact of specific genetic variants on the interindividual variability in CYP2D6-mediated drug metabolism remains insufficiently quantified. This translational study sought to address this gap by analyzing the genotypes and phenotypes of patients in two large clinical cohorts, focusing on the metabolism of the CYP2D6 substrates risperidone and desmethyltamoxifen. The analysis incorporated novel polymorphic haplotypes and substrate-specific differences among the CYP2D6.1, CYP2D6.2, and CYP2D6.35 enzyme variants. The study revealed that CYP2D6.2 and CYP2D6.35 exhibit reduced metabolic capacity for these substrates, both in vivo and in an in vitro expression model. This was evidenced by decreased catalytic turnover (Kcat), decreased substrate affinity, and altered substrate docking. Furthermore, novel polymorphic haplotypes on the CYP2D6*1, CYP2D6*2, and CYP2D6*35 backgrounds were identified, each associated with a 30-40% increase in CYP2D6 activity. Incorporating these findings into prediction equations significantly improved the genetic prediction accuracy (R2) for CYP2D6-mediated metabolism of desmethyltamoxifen from 59% to 71% and risperidone, also metabolized by CYP3A4, from 42% to 46%. These results highlight the importance of accounting for drug-specific interactions with enzyme variants and integrating distinct polymorphic haplotypes into CYP pharmacogenomic models and guidelines for better translation into clinical practice.
引用
- Johansson I, Xanthopoulou EM, Zhou Y, et al. Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account. Clin Pharmacol Ther. 2025. PMID: 40261922. doi:10.1002/cpt.3680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。